

■ **Alendronic acid has significantly greater effects than risedronic acid on bone mineral density (BMD) in postmenopausal women with osteoporosis**, according to further results from the Fosamax Actonel Comparison Trial-international study.\* This double-blind, randomised study included 936 women who received oral alendronic acid 70mg once weekly (n = 468) or oral risedronic acid 35mg once weekly. At 24 months, increases from baseline in hip trochanter BMD were significantly greater in the 366 evaluable women receiving alendronic acid, compared with 350 women receiving risedronic acid (treatment difference 1.5%). The group receiving risedronic acid also had significantly larger decreases in bone turnover marker levels. There was no significant difference in tolerability between the two treatment groups.

\* This trial was funded by a grant from Merck & Co.

Reid DM, et al. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. *International Journal of Clinical Practice* 62: 575-584, No. 4, Apr 2008

801110315